Rescuing the last-line polymyxins: achievements and challenges
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
[HTML][HTML] Epidemiology and characteristics of metallo-β-lactamase-producing Pseudomonas aeruginosa
DJ Hong, IK Bae, IH Jang, SH Jeong… - Infection & …, 2015 - ncbi.nlm.nih.gov
Metallo-β-lactamase-producing Pseudomonas aeruginosa (MPPA) is an important
nosocomial pathogen that shows resistance to all β-lactam antibiotics except monobactams …
nosocomial pathogen that shows resistance to all β-lactam antibiotics except monobactams …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
BT Tsuji, JM Pogue, AP Zavascki… - … : The Journal of …, 2019 - Wiley Online Library
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs
EI Nielsen, LE Friberg - Pharmacological reviews, 2013 - ASPET
Pharmacokinetic-pharmacodynamic (PKPD) modeling and simulation has evolved as an
important tool for rational drug development and drug use, where developed models …
important tool for rational drug development and drug use, where developed models …
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse …
Objectives This study investigated the exposure–response relationships between unbound
colistin in plasma and antibacterial activity in mouse thigh and lung infections. Methods …
colistin in plasma and antibacterial activity in mouse thigh and lung infections. Methods …
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans
JB Bulitta, WW Hope, AE Eakin, T Guina… - Antimicrobial agents …, 2019 - Am Soc Microbiol
ABSTRACT In June 2017, the National Institute of Allergy and Infectious Diseases, part of
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives
DF Bavaro, A Belati, L Diella, M Stufano, F Romanelli… - Antibiotics, 2021 - mdpi.com
Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-
negative bacteria. We report our experience with cefiderocol-based combination therapies …
negative bacteria. We report our experience with cefiderocol-based combination therapies …
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
The polymyxin antibiotics [colistin and polymyxin B (PMB)] are increasingly used as a last-
line option for the treatment of infections caused by extensively drug-resistant Gram …
line option for the treatment of infections caused by extensively drug-resistant Gram …
Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill
AF Mohamed, I Karaiskos, D Plachouras… - Antimicrobial agents …, 2012 - Am Soc Microbiol
ABSTRACT A previous pharmacokinetic study on dosing of colistin methanesulfonate (CMS)
at 240 mg (3 million units [MU]) every 8 h indicated that colistin has a long half-life, resulting …
at 240 mg (3 million units [MU]) every 8 h indicated that colistin has a long half-life, resulting …
Agents of last resort: polymyxin resistance
The polymyxins, colistin (also known as polymyxin E) and polymyxin B, have a unique and
interesting history. Originally introduced in the 1950s for the treatment of infections due to …
interesting history. Originally introduced in the 1950s for the treatment of infections due to …